Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024
Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410
Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference
Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished
FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate